ADORA2A and neoplasm: Therefore, a NIR-II light-activatable nanomedicine(ASPA) was prepared by encapsulating a fluorescent dye (NIR775) inNIR-II light-absorbing SP backbone-based NPs (ASPA), followed by surfacemodification with an A2AR antagonist (vipadenant, VIPA) through anazo-based thermosensitive linker (Figure 13A, Table 5).187 Upon NIR-II photoirradiationat the tumor site, ASPA exerted PTT effects to promote the rapid releaseof VIPA by inducing cleavage of the thermolabile linker (Figure 13A).